New trial
Comparison of I-124 PET/CT to I-123 Imaging for Metastatic Thyroid Cancer
- Trial ID
- NCT06961084 on ClinicalTrials.gov
- Cancer type
- Thyroid Cancer
- Published in
- New in Oncology - May 21, 2025
This single-arm prospective study compares the efficacy of I-124 PET/CT with traditional I-123/I-131 imaging in metastatic thyroid cancer patients, using an oral dose of I-124 followed by PET/CT scanning 20–28 hours later and a short safety follow-up.
More in thyroid cancer
-
Trial result · Oct 22, 2026 · NCT03899792
Selpercatinib (selective RET inhibitor) posts 53% ORR with 2-year durability in pediatric RET-altered tumors -
Trial result · Aug 13, 2026 · NCT04940052
Dabrafenib + trametinib (BRAF/MEK) cuts progression risk in BRAF V600E thyroid cancer -
Trial result · Aug 13, 2026 · NCT03181100
Atezolizumab (PD-L1) + MAPK-targeted therapy links ATC long survival to “inflamed + differentiated” tumors, not BRAF/RAS status -
Trial result · Jul 8, 2026 · NCT03037385
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC -
Trial result · Jul 8, 2026 · NCT03669432
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer